EU/3/20/2300

About

On 27 July 2020, orphan designation EU/3/20/2300 was granted by the European Commission to Aneuryst (Ireland) Limited, Ireland, for fasudil hydrochloride for the treatment of non-traumatic subarachnoid haemorrhage.

Key facts

Active substance
Fasudil hydrochloride
Disease / condition
Treatment of non-traumatic subarachnoid haemorrhage
Date of first decision
27/07/2020
Outcome
Positive
EU designation number
EU/3/20/2300

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Inniscarra
Main Street, Rathcoole
Dublin
Ireland
Tel: + 12126711068
E-mail: info@aneuryst.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating